Document is current

Article History

Received: 14 August 2023

Accepted: 18 April 2024

First Online: 19 June 2024

Competing interests

: H.H. is an employee of Eisai. He serves as a reviewing editor for the journal <i>Alzheimer’s & Dementia</i>. He is an inventor of 11 patents and has received no royalties: In Vitro Multiparameter Determination Method for the Diagnosis and Early Diagnosis of Neurodegenerative Disorders, patent number 8916388; In Vitro Procedure for Diagnosis and Early Diagnosis of Neurodegenerative Diseases, patent number 8298784; Neurodegenerative Markers for Psychiatric Conditions, publication number 20120196300; In Vitro Multiparameter Determination Method for the Diagnosis and Early Diagnosis of Neurodegenerative Disorders, publication number 20100062463; In Vitro Method for the Diagnosis and Early Diagnosis of Neurodegenerative Disorders, publication number 20100035286; In Vitro Procedure for Diagnosis and Early Diagnosis of Neurodegenerative Diseases, publication number 20090263822; In Vitro Method for the Diagnosis of Neurodegenerative Diseases, patent number 7547553; CSF Diagnostic In Vitro Method for Diagnosis of Dementias and Neuroinflammatory Diseases, publication number 20080206797; In Vitro Method for the Diagnosis of Neurodegenerative Diseases, publication number 20080199966; Neurodegenerative Markers for Psychiatric Conditions, publication number 20080131921; Method for diagnosis of dementias and neuroinflammatory diseases based on an increased level of procalcitonin in cerebrospinal fluid, publication number: United States patent 10921330. D.M.H. cofounded, has equity in and is on the scientific advisory board of C2N Diagnostics. He is on the scientific advisory board of Denali, Cajal Neuroscience and Genentech and consults for Alector. He is an inventor on US patent application US-20190270794-A1, ‘Anti-ApoE antibodies’. Anti-ApoE antibodies and this patent application have been licensed by Washington University the NextCure. L.G.A. receives research support from the NIH, the Alzheimer Association, AVID Pharmaceuticals, Life Molecular Imaging, Roche Diagnostics and Eli Lilly. L.G.A. has served as a consultant for Biogen, Two Labs, IQVIA, the NIH, the Florida Department of Health, Siemens, Corium, the NIH Biobank, Eli Lilly, Eisai, GE Healthcare, Roche Diagnostics, Alnylam and Genentech. L.G.A. is a member of various data and safety monitoring boards and advisory boards for IQVIA, NIA R01 AG061111, the UAB Nathan Schick Center, the FDA PCNS Advisory Board and the University New Mexico ADRC. L.G.A. serves in a leadership or fiduciary role at the Medical and Scientific Council of the Alzheimer’s Association Greater Indiana Chapter, the Alzheimer’s Association Science Program Committee, the FDA PCNS Advisory Committee and the Beeson Program Committee. L.G.A. has received equipment, materials, drugs, medical writing, gifts or other services from AVID Pharmaceuticals, Life Molecular Imaging and Roche Diagnostics. L.G.A. owns stock in Cassava Neurosciences and Golden Seeds. C.C. has received research support from GSK. C.C. is a member of the advisory board of Vivid Genomics and Circular Genomics and owns stocks. C.L.M. has no competing interests to declare. J.H. has consulted for Eisai and Eli Lilly. V.L.V. serves as a senior associate editor for the <i>Journal of Neurochemistry</i>. He has been a consultant for IXICO and Life Molecular Imaging and has received speaker honoraria from GE Healthcare, Piramal Lifesciences and Eli Lilly. M.C., J.B. and S.N. are employees of Eisai.